The EZH2 mutation rate in the different AML subgroups was 12% (3/25) in de novo AML, 9% (2/22) in AML with myelodysplasia-related changes (MRC), and 25% (1/4) in therapy-related AML (t-AML). The gene discussed is EZH2; the disease is Myelodysplasia.